Regeneron Pharmaceuticals Aktie News

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also developing newer medicines that will improve its financial results.

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow transplants, preliminary data from a small mid-stage trial suggest.

Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin. Moreover, as of September 30, Regeneron had about $2.2 billion remaining under its authorized share repurchase program, underscoring its ongoing efforts to create long-term value for its investors. However, I believe the European Commission's approval of Dupixent for the treatment of chronic spontane...

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time

Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the first part of a late-stage trial.

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript